The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Head and Neck Cancer
HEAD AND NECK CANCER ADVISOR
FEATURED CONTENT
-
-
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments. -
The Unexpected Costs of Cancer Treatment: Out-of-Network Billing
The cancer field is not immune to the challenges of out-of-network and surprise billing. -
Preclinical Work on Red Blood Cell-Based Therapies in HPV-Positive Solid Tumors Provides Rationale for Clinical Trials in Humans
A microfluidics platform for engineering activated antigen carrier immunotherapies from red blood cells showed promising preliminary results in a mouse model. -
The FDA Approval Process Needs Refinement, Not a Total Overhaul
Even though overall drug development times have not changed, questions about the clinical benefit of the drugs that have been approved through expedited pathways are being raised.
HEAD AND NECK CANCER NEWS
Short-Term Mortality Risks Appear Higher in HPV-Negative Oropharyngeal Cancer
Endoscopic Approaches Feasible in Surgery for Sinonasal Cancer
Pembrolizumab Prolongs Survival in Advanced Head, Neck Cancer
Delaying Treatment Worsens Head, Neck Cancer Outcomes
Adjuvant Radiation Therapy Improved Outcomes for Some With Advanced Head and Neck CSCC
Want to read more?
Please login or register first to view this content.
Next post in Head and Neck Cancer
